Spots Global Cancer Trial Database for allogeneic hematopoietic cell transplantation
Every month we try and update this database with for allogeneic hematopoietic cell transplantation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation | NCT05873205 | Blood Cancer Refractory Immu... | Isatuximab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation | NCT05873205 | Blood Cancer Refractory Immu... | Isatuximab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia | NCT01677949 | Acute Myeloid L... Acute Lymphobla... | Clofarabine Etoposide Cyclophosphamid... allogeneic hema... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) | NCT00185523 | Leukemia, Lymph... Leukemia Leukemia Acute ... Leukemia Acute ... Leukemia Chroni... Leukemia Acute ... Leukemia Chroni... | Allogeneic hema... | 4 Weeks - 55 Years | Stanford University | |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | NCT02646839 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | CliniMacs TCR a... | - 21 Years | Children's Hospital Los Angeles | |
| Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia | NCT01677949 | Acute Myeloid L... Acute Lymphobla... | Clofarabine Etoposide Cyclophosphamid... allogeneic hema... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| A Study of FMT in Patients With AML Allo HSCT in Recipients | NCT03678493 | Acute Myeloid L... Allogeneic Hema... | Fecal Microbiot... Placebo | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Comparing Post-Transplant Cyclophosphamide as GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients | NCT04314219 | Acute Lymphobla... Acute Myeloid L... | Cyclophosphamid... Methotrexate | 14 Years - 65 Years | King Faisal Specialist Hospital & Research Center | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation | NCT01081405 | HEMATOLOGIC MAL... | TOTAL LYMPHOID ... | 50 Years - 70 Years | Fondazione EMN Italy Onlus | |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | NCT02646839 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | CliniMacs TCR a... | - 21 Years | Children's Hospital Los Angeles | |
| Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma | NCT00847639 | Multiple Myelom... | lenalidomide | 18 Years - 70 Years | Center for International Blood and Marrow Transplant Research | |
| Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation | NCT01081405 | HEMATOLOGIC MAL... | TOTAL LYMPHOID ... | 50 Years - 70 Years | Fondazione EMN Italy Onlus | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) | NCT00185523 | Leukemia, Lymph... Leukemia Leukemia Acute ... Leukemia Acute ... Leukemia Chroni... Leukemia Acute ... Leukemia Chroni... | Allogeneic hema... | 4 Weeks - 55 Years | Stanford University | |
| TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | NCT01883219 | Philadelphia Ch... Stem Cell Trans... Minimal Residua... | TKIs | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | NCT00698685 | Leukemia Lymphoma Hodgkin's Disea... Hematologic Neo... Multiple Myelom... Carcinoma, Rena... | Pentostatin Alemtuzumab Allogeneic hema... | 18 Years - 75 Years | University of Arizona | |
| Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma | NCT00847639 | Multiple Myelom... | lenalidomide | 18 Years - 70 Years | Center for International Blood and Marrow Transplant Research | |
| Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma | NCT00847639 | Multiple Myelom... | lenalidomide | 18 Years - 70 Years | Center for International Blood and Marrow Transplant Research | |
| Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma | NCT00302757 | Non-Hodgkin Lym... | Radioimmunother... allogeneic hema... | 18 Years - 70 Years | University Hospital Tuebingen | |
| Allogeneic SCT for CML, TKI Failure After TKI Failure | NCT02172365 | Chronic Myeloid... | 18 Years - 70 Years | University Health Network, Toronto | ||
| A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) | NCT05736419 | Sickle Cell Dis... Thalassemia, Be... Thalassemia | Fludarabine Cyclophosphamid... Tacrolimus Mycophenolate M... Rabbit ATG Dexamethasone Bortezomib Rituximab | 2 Years - 50 Years | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
